Análisis de los diferentes marcadores tumorales y su importancia en el cáncer de mama

Jefferson Reinaldo  Orellana Lozano; Cristóbal Rolando  Barcia Menéndez

doi:10.59169/pentaciencias.v5i3.519

Authors

Jefferson Reinaldo Orellana Lozano Universidad Estatal del Sur de Manabí https://orcid.org/0000-0001-9965-8344
Cristóbal Rolando Barcia Menéndez Universidad Estatal del Sur de Manabí https://orcid.org/0000-0002-7851-5763

DOI:

https://doi.org/10.59169/pentaciencias.v5i3.519

Keywords:

Cancer; mammary gland; breast cancer; breast diseases; tumor marker.

Abstract

Breast cancer is the most recurrent neoplasm in developed and underdeveloped territories; its incidence is increasing despite prevention and early detection measures. The main objective of the study was to analyze the existing bibliographic evidence on tumor markers and their importance in breast cancer. A retrospective, retrospective, qualitative, descriptive and non-experimental documentary review was applied in a final sample of 30 literary sources published between the years 2018-2022 in the databases PubMed, SciELO, Redalyc, Medigraphic. Reaching that, the factors that constitute an influential risk circumscribe from those modifiable (overweight, alcohol, sedentary lifestyle, early menarche, parity and first gestation at advanced ages) to those that cannot be alterable (ethnicity, race and genetic components), while its prevalence lies in maintaining itself as one of the main origins of death in the world. On the other hand, it was also evident that biomarkers constitute a means of prognosis and prediction for cancer patients. The importance of carbohydrate antigen 15-3 and carcinoembryonic antigen markers lies in their association with tumors that have a greater tumor burden, more aggressive faculties and the danger of triggering metastasis, thus making them a predictive element without dependence. Interest in the management of biomarkers such as CA 15-3 and CEA in neoplastic disease and early detection of breast cancer metastases is more common. Emphasizing that of the 2, CA 15-3 showed greater sensitivity in breast cancer than carcinoembryonic antigen.

Downloads

Download data is not yet available.

References

Bonilla, O. (2020. [citado 30 de noviembre de 2022]). Marcadores tumorales en cáncer de mama. Revisión sistemática. Ginecología y obstetricia de México. [en linea], 88(12), 860-869. https://doi.org/810.24245/gom.v24288i24212.24269

Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. (2018.). Disease markers. [en linea], 9863092, https://pubmed.ncbi.nlm.nih.gov/29854028/.

Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Di Lauro, V., Fusco, G., & col, y. (2020. [citado 30 de noviembre de 2022]). Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int. J. Mol. Sci. [en linea], 21(13), 4579; https://doi.org/4510.3390/ijms21134579.

Coughlin, S. (2019. [Citado 20 de noviembre de 2022]). Epidemiology of Breast Cancer in Women. Adv Exp Med Biol. [en linea], 1152, 9-29. doi: 10.1007/1978-1003-1030-20301-20306_20302. .

Chen, X., Wang, Q., Zhang, Y., Xie, Q., & Tan, X. (2019. [citado 30 de noviembre de 2022]). Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports. Value in Health. [en linea], 22(1), 104-128. https://www.valueinhealthjournal.com/article/S1098-3015(1018)32322-32322/fulltext?_returnURL=https%32323A%32322F%32322Flinkinghub.elsevier.com%32322Fretrieve%32322Fpii%32322FS1098301518323222%1098301518323223Fshowall%1098301518323223Dtrue.

Chokoev, A., Akhunbaev, S., Kudaibergenova, I., Soodonbekov, E., Kulayev, K., Ospanov, K., Kuandykov, Y., Telmanova, Z., Makimbetov, E., & Igissinov, N. (2022). Breast Cancer Incidence in Kyrgyzstan: Report of 15 Years of Cancer Registry. Asian Pac J Cancer Prev. [en linea], 23(5), 1603-1610. doi: 1610.31557/APJCP.32022.31523.31555.31603. PMID: 35633544; PMCID: PMC39587886.

Fujimoto, Y., Higuchi, T., Nishimukai, A., Miyagawa, Y., Kira, A., & col, y. (2018. [citado 30 de noviembre]). High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy. Journal of Surgical Oncology. [en linea], 118(1), 228-237. https://onlinelibrary.wiley.com/doi/210.1002/jso.25125.

Husby, A., Wohlfahrt, J., Oyen, N., & Melbye, M. (2018. [citado 30 de noviembre de 2022]). Pregnancy duration and breast cancer risk. Nat Commun. [en linea], 9, 4255. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199327/.

Imamura, M., Morimoto, T., Nomura, T., & col, y. (2018. [citado 30 de noviembre del 2022]). Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Onc. [en linea], 16(26), https://wjso.biomedcentral.com/articles/10.1186/s12957-12018-11325-12956#citeas.

Iyengar, N., Arthur, R., Manson, J., Chlebowski, R., Kroenke, C., Peterson, L., Cheng, T., Feliciano, E., & col, y. (2019. [citado 28 de noviembre de 2022]). Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index. JAMA Oncol. [en linea], 5(2), 155–163. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439554/.

Khushk M, K. A., Rehman A, Sheraz S, Tunio YM, Rehman K, Rehman D, Ahmed M. (2021). The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer. Cureus. [en linea[], 13(7), https://pubmed.ncbi.nlm.nih.gov/34405063/.

Kluźniak, W., Wokołorczyk, D., Rusak, B., Huzarski, T., Gronwald, J., Stempa, K., & al, e. (2019. [citado 20 de diciembre de 2022]). Polish Hereditary Breast Cancer Consortium. Inherited variants in XRCC2 and the risk of breast cancer. Breast Cancer Res Treat. [en linea], 178(3), 657-663. doi: 610.1007/s10549-10019-05415-10545.

Li, S., Wei, X., He, J., Tian, X., & Yuan, S. (2018. [citado 30 de noviembre de 2022]). Plasminogen activator inhibitor-1 in cancer research. Biomedicine & Pharmacotherapy, 105(1), 83-94. https://www.sciencedirect.com/science/article/abs/pii/S0753332218319528?via%0753332218319523Dihub.

Li, S., Yulan, Z., Qi, Q., & Liming, T. (2018. [citado 27 de noviembre de 2022]). Body mass index and prognosis of breast cancer An analysis by menstruation status when breast cancer diagnosis. Medicine. [en linea], 97(26), https://journals.lww.com/md-journal/Fulltext/2018/06290/Body_mass_index_and_prognosis_of_breast_cancer__An.06241.aspx.

Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021. [citado 28 de noviembre de 2022]). Breast cancer. Lancet. [en linea], 397(10286), 1750-1769. https://pubmed.ncbi.nlm.nih.gov/33812473/.

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021. [citado 30 de noviembre de 2022]). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers (Basel). [en linea], 13(17), 4287. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428369/.

Ma, J., Qin, L., & Li, X. (2020. [citado 30 de noviembre de 2022]). Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. [en linea], 18(33), https://biosignaling.biomedcentral.com/articles/10.1186/s12964-12020-10527-z#citeas.

Marcador tumoral CA 15-3 en carcinoma invasivo de mama de tipo no especial (ductal). (2022.). Anatomia digital. [en linea], 5(3), 58-75. https://www.cienciadigital.org/revistacienciadigital52/index.php/AnatomiaDigital/article/view/2331/5635.

Marcadores tumorales en cáncer de mama. Revisión sistemática. (2020). Revista de Ginecología y obstetricia de México. https://doi.org/10.24245/gom.v88i12.4269, 88(2).

Nicolini, A., Carpi, A., P, F., Morganti, R., & Mazzoti, V. (2018. [citado 30 de noviembre de 2022]). An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res. [en linea], 10, 6879-6886. https://www.dovepress.com/an-individual-reference-limit-of-the-serum-cea-tpa-ca-6815-6873-tumor-marke-peer-reviewed-fulltext-article-CMAR.

Paizula, X., Mutailipu, D., Xu, W., Wang, H., & Yi, L. (2022. [citado 30 de noviembre de 2022]). Identification of biomarkers related to tumorigenesis and prognosis in breast cancer. Gland Surg. [en linea], 11(9), 1472-1488. doi: 1410.21037/gs-21022-21449.

Pusina, S. (2018. [citado el 29 de noviembre del 2022]). Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. Med Arch. [en linea], 72(5), 335-340. doi: 310.5455/medarh.2018.5472.5335-5340.

Rainville, I., Hatcher, S., Rosenthal, E., Larson, K., Bernhisel, R., Meek, S., Gorringe, H., Mundt, E., & Manley, S. (2020. [Citado 27 de noviembre del 2022]). High risk of breast cancer in women with biallelic pathogenic variants in CHEK2. Breast Cancer Res Treat. [en linea], 180(2), 503-509. doi: 510.1007/s10549-10020-05543-10543.

Sagi, L., Lavie, O., Auslander, R., & Sagi, S. (2018. [citado 30 de noviembre de 2022]). Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature. Am J Clin Oncol. [en linea], 41(9), 838-844. doi:810.1097/COC.0000000000000383.

Santiesteban, B., Pizarro, R., & Hernández, F. (2021. [citado 29 de noviembre del 2022]). Antígeno carbohidratado 15.3 en el seguimiento del cáncer de mama. Revista Estudiantil HolCien. [en linea], 2(2), http://www.revholcien.sld.cu/index.php/holcien/article/view/148/155.

Smaradhania, N., Rahman, S., Ardi, S., & Prihantono, P. (2021. [citado). Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer. Breast Dis. [en linea], 40(1), 1-7. https://pubmed.ncbi.nlm.nih.gov/34057113/.

Zeinomar, N., Knight, J., Genkinger, J., Phillipd, K., Daly, M., Milne, R., & col, y. (2019. [citado 30 de noviembre de 2022]). Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research. [en linea], 21, 128. https://breast-cancer-research.biomedcentral.com/articles/110.1186/s13058-13019-11213-13051#citeas.

Zhao, W., Li, X., Wang, W., Chen, B., Wang, L., Zhang, N., Wang, Z., & Yang, Q. (2021. [citado 30 de noviembre de 2022]). Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer. Disease markers. [ en linea], 55, https://pubmed.ncbi.nlm.nih.gov/34621407/.